We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SBT
876
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $465K | ﹤0.01% |
102,219
+80,895
| +379% | +$393K |
|
877
Neuronetics
STIM
$120M
| $464K | ﹤0.01% |
28,944
| – | – |
|
|
ABTX
878
DELISTED
Allegiance Bancshares
ABTX
| $464K | ﹤0.01% |
12,071
+3,291
| +37% | +$133K |
|
|
BCEL
879
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $462K | ﹤0.01% |
54,190
+39,330
| +265% | +$403K |
|
880
Home Bancorp
HBCP
$552M
| $460K | ﹤0.01% |
12,075
-70
| -0.6% | -$2.67K |
|
|
SNV
881
DELISTED
Synovus
SNV
| $458K | ﹤0.01% |
+10,429
| New | +$490K |
|
882
Axcelis
ACLS
$4.12B
| $457K | ﹤0.01% |
11,299
-21,022
| -65% | -$871K |
|
|
SYBX
883
DELISTED
Synlogic
SYBX
| $450K | ﹤0.01% |
7,704
-11,137
| -59% | -$608K |
|
884
LifeVantage
LFVN
$82.4M
| $445K | ﹤0.01% |
60,578
-48,761
| -45% | -$398K |
|
885
Outlook Therapeutics
OTLK
$264M
| $444K | ﹤0.01% |
8,925
| – | – |
|
|
DZSI
886
DELISTED
DZS Inc. Common Stock
DZSI
| $444K | ﹤0.01% |
21,374
-16,817
| -44% | -$292K |
|
887
Playtika
PLTK
$1.4B
| $438K | ﹤0.01% |
+18,378
| New | +$481K |
|
|
NWHM
888
DELISTED
THE NEW HOME COMPANY INC.
NWHM
| $438K | ﹤0.01% |
74,558
+27,992
| +60% | +$171K |
|
889
Nektar Therapeutics
NKTR
$2.39B
| $437K | ﹤0.01% |
1,699
+392
| +30% | +$108K |
|
890
Educational Development Corp
EDUC
$12.4M
| $435K | ﹤0.01% |
35,066
+2,066
| +6% | +$31.8K |
|
891
Rackspace Technology
RXT
$1B
| $430K | ﹤0.01% |
+21,943
| New | +$486K |
|
892
CNB Financial Corp
CCNE
$1.03B
| $428K | ﹤0.01% |
18,769
+3,271
| +21% | +$79.8K |
|
893
First Commonwealth Financial
FCF
$2.12B
| $428K | ﹤0.01% |
30,395
| – | – |
|
894
Paysign
PAYS
$486M
| $426K | ﹤0.01% |
+134,044
| New | +$482K |
|
|
CWBC
895
Community West Bancshares
CWBC
$678M
| $425K | ﹤0.01% |
21,097
| – | – |
|
|
CERE
896
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $420K | ﹤0.01% |
+16,376
| New | +$234K |
|
897
Aquestive Therapeutics
AQST
$462M
| $417K | ﹤0.01% |
104,934
-33,448
| -24% | -$134K |
|
898
Universal Logistics Holdings
ULH
$416M
| $416K | ﹤0.01% |
+17,838
| New | +$445K |
|
899
Spyre Therapeutics
SYRE
$8.87B
| $413K | ﹤0.01% |
2,372
-5,205
| -69% | -$946K |
|
|
CALA
900
DELISTED
Calithera Biosciences, Inc
CALA
| $409K | ﹤0.01% |
9,780
-1,744
| -15% | -$76.6K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.